Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Survival outcomes for first-line antiretroviral therapy in India’s ART program

  • Rakhi Dandona1Email author,
  • Bharat B. Rewari2, 3,
  • G. Anil Kumar1,
  • Sukarma Tanwar1, 2, 3,
  • S. G. Prem Kumar1,
  • Venkata S. Vishnumolakala1,
  • Herbert C. Duber4,
  • Emmanuela Gakidou4 and
  • Lalit Dandona1, 4
BMC Infectious DiseasesBMC series – open, inclusive and trusted201616:555

https://doi.org/10.1186/s12879-016-1887-2

Received: 18 May 2016

Accepted: 1 October 2016

Published: 11 October 2016

Abstract

Background

Little is known about survival outcomes of HIV patients on first-line antiretroviral therapy (ART) on a large-scale in India, or facility level factors that influence patient survival to guide further improvements in the ART program in India. We examined factors at the facility level in addition to patient factors that influence survival of adult HIV patients on ART in the publicly-funded ART program in a high- and a low-HIV prevalence state.

Methods

Retrospective chart review in public sector ART facilities in the combined states of Andhra Pradesh and Telangana (APT) before these were split in 2014 and in Rajasthan (RAJ), the high- and a low-HIV prevalence states, respectively. Records of adults initiating ART between 2007-12 and 2008-13 in APT and RAJ, respectively, were reviewed and facility-level information collected at all ART centres and a sample of link ART centres. Survival probability was estimated using Kaplan-Meier method, and determinants of mortality explored with facility and patient-level factors using Cox proportional hazard model.

Results

Based on data from 6581 patients, the survival probability of ART at 60 months was 76.3 % (95 % CI 73.0–79.2) in APT and 78.3 % (74.4–81.7) in RAJ. The facilities with cumulative ART patient load above the state average had lower mortality in APT (Hazard ratio [HR] 0.74, 0.57–0.95) but higher in RAJ (HR 1.37, 1.01–1.87). Facilities with higher proportion of lost to follow-up patients in APT had higher mortality (HR 1.47, 1.06–2.05), as did those with higher ART to pre-ART patient ratio in RAJ (HR 1.62, 1.14–2.29). In both states, there was higher hazard for mortality in patients with CD4 count 100 cells/mm3 or less at ART initiation, males, and in patients with TB co-infection.

Conclusions

These data from the majority of facilities in a high- and a low-HIV burden state of India over 5 years reveal reasonable and similar survival outcomes in the two states. The facilities with higher ART load in the longer established ART program in APT had better survival, but facilities with a higher ART load and a higher ratio of ART to pre-ART patients in the less experienced ART program in RAJ had poorer survival. These findings have important implications for India’s ART program planning as it expands further.

Keywords

AIDS ART HIV India Mortality Survival

Background

Over the last decade, the HIV program in India has been scaled up substantially to reduce mortality and morbidity from HIV/AIDS and to improve the quality of life of those infected by HIV. The rapid scale-up of antiretroviral treatment (ART) services in recent years has improved access to ART with provision of free ART under the National AIDS Control Program (NACP- IV) [1].

The HIV program in India aims for evidence-based planning for further ART roll-out and performance monitoring [2]. However, there is a paucity of literature on survival outcomes of HIV patients on ART on a large-scale in India. The available reports are based on small samples of HIV patients, data limited to a single treatment centre, survival outcomes with TB as comorbidity, or have explored only the individual level predictors for survival on ART [37]. At the time of designing the study in 2012-13, our aim was to document survival outcomes and analyse the individual level and facility level predictors of survival for HIV patients on first-line ART in NACP-IV in two Indian states - Andhra Pradesh and Rajasthan. Andhra Pradesh in south India had a population of about 85 million population at that time, and the highest number of persons with HIV among any Indian state with a long-standing ART program. On the other hand, Rajasthan in north India had a population of about 70 million, and a relatively lower HIV burden with a more recent ART program [8]. Heterosexual mode of transmission is the major HIV infection route in both states [8].

Methods

After data collection was completed in 2013, the state of Telangana was carved out of Andhra Pradesh state in June 2014. As data were collected prior to this split, we report findings for the undivided Andhra Pradesh that includes the current Andhra Pradesh and Telangana (APT) and for Rajasthan (RAJ).

Ethics approval for this study was obtained from Ethics Committees of the Public Health Foundation of India, New Delhi and the University of Washington, Seattle, USA. The study was approved by the Indian Council for Medical Research, Health Ministry Steering Committee, the Government of India and by the National AIDS Control Organization of India.

Sample of ART facilities

In India, ART services are provided by ART centres and Link ART centres (LAC). ART centre provides pre-ART and ART services to HIV infected people, and LAC is an extension of ART centre which were established to minimize the travel need and related costs for ART patients to receive basic ART services [8]. Patients on ART are registered with ART centre to start treatment and once stable are then transferred to LAC to receive medications on a routine basis. In this study, for APT all 45 ART centres and one LAC for each ART functional in 2012 were randomly sampled. A total of 41 LACs were subsequently sampled as four ART centres in the state capital Hyderabad had no LAC. In RAJ all 16 ART centres and all 27 link ART centres functional in 2012 were sampled, of which 10 LAC were newly established, and hence data were not available for these for this study.

Patient clinical record data

The ART patient’s clinical record (known as white card) is maintained at the facilities that provide ART services. It is used to document demographic information of the patient; risk factors; and various treatment and clinical details, and follow-up details for each visit. We aimed to sample 75 and 35 adult patient records at each ART centre and LAC, respectively in APT, for the last five financial years at the time of starting data collection (April 2007 to March 2012). For RAJ, the aimed sample was 180 and 30 adult patient records at each ART centre and LAC, respectively, during the last 5 financial years at the time of starting data collection (April 2008 to March 2013). With this approach, at least 3000 adult patients on ART were finally expected to be part of the study in each state. Only records of patients who were initiated on first line ART between 6 and 60 months prior to the date of data collection were considered eligible. We used the ART enrolment register which includes documentation of the ART initiation date for each patient to arrive at the total number of eligible adult patient records at each facility. We then used a pre-defined sampling strategy to sample the eligible patient records at each ART facility - the total number of adult patients who had initiated ART within the inclusion time period was divided by the required number of adult patient records to be sampled to arrive at the sampling interval. A random number was picked within this sampling interval to select the first record, and then the records were sampled systematically using the sampling interval until the desired sample was achieved.

Data collection procedure

Data were collected electronically using Datstat Illume Survey Manager 5.1 (DatStat Inc., Seattle, WA). The program used for capturing data was a replica of the white card. Data extractors trained in study procedures recorded data “as is” from the white cards to reflect the actual data in each white card. The current status of the patient (alive, dead, lost to follow-up, or transferred to another facility) was recorded from the ART enrolment register. Ten percent or more of data collected were checked daily by the field team supervisor to ensure the quality of data collected. Formal consent of the senior-most person responsible at each ART facility was obtained to collect these data. Data were collected in APT from February to May 2013 and in RAJ during June-July 2013.

Data analysis

Survival probability

The probability of survival of HIV patients on ART at 12 and 60 months was estimated using the Kaplan-Meier product limit estimation method. The duration of survival was calculated from the month of ART initiation to the month of death or to the last visit for the alive patients. Censoring based on the last date of visit to the ART was done for patients who were lost to follow-up (LFU) or transferred out of the facility. We report overall survival probability of HIV patients on ART at 12 and 60 month for the two sexes and by baseline CD4 cell count. As mortality at the facility level is mostly not captured among HIV patients who were LFU, we adjusted the survival with mortality among LFU patients as shown in the equation below that has been previously used in the literature: [9]
$$ \mathrm{S}\left(\mathrm{t}\right) = 1 - \left[\mathrm{ML}\left(\mathrm{t}\right) + \mathrm{L}\left(\mathrm{t}\right)*\mathrm{M}\mathrm{N}\mathrm{L}\left(\mathrm{t}\right)\right] $$
where S(t) = adjusted ART survival in last 5 years; L(t) = Proportion of LFU patients in 5 years; ML(t) = Mortality estimated in LFU patients; and MNL(t) = Mortality observed in patients in care (1- predicted Kaplan-Meier survival estimates).
As an inverse relation between mortality among LFU patients and the rate of LFU in the ART program has been previously reported from an analysis of several HIV programs in Africa, we used the following equation from this analysis to estimate mortality among LFU patients in each facility in APT and RAJ: [9]
$$ {\mathrm{ML}}_{\mathrm{i}}= \exp\ \left(\mathrm{a} + {\mathrm{br}}_{\mathrm{i}}\right)/\left(1 + \exp\ \left(\mathrm{a} + {\mathrm{br}}_{\mathrm{i}}\right)\right) $$
where MLi = mortality among non-LFU patients in each facility, r = proportion of LFU patients in each facility, a = 0.57287 and b = −4.04409.

Finally, we calculated the weighted average of ML for each state by using the total patients on ART in each facility in each state. The weighted average of estimated mortality among LFU patients was 0.43 for APT and 0.61 for RAJ at 5 years. We considered 20 % lower and higher levels than the point estimates for ML(t) for sensitivity analysis for the probabilities of ART survival, which was performed using Monte Carlo simulations by doing 100,000 iterations with the @Risk software (Palisade UK Europe Ltd). We used random values between these plausible ranges to obtain the 95 % uncertainty interval (UI) for the probabilities of survival estimates. We report survival probability at 60 months that is adjusted for LFU mortality.

Predictors of mortality

Cox proportional hazard model was used to determine the predictors of mortality with select patient demography and clinical indicators (ART regimen, CD4 count at start of ART, co-existing tuberculosis, history of alcohol use). We also included facility related variables - cumulative ART patient load at ART centre, ratio of cumulative ART patients to pre-ART patients, and percent of cumulative LFU patients. The cumulative data over the 5-year study period was used to calculate the average value for each of these variables per state. Facilities were categorised as having below/equal or above the average value for cumulative ART patient load and ratio of cumulative ART patients to pre-ART patients; and were categorised into three equal groups based on the percent of cumulative LFU patients for the analysis. For this analysis, the ART patients undergoing treatment at LAC were considered together with the parent ART centre which was their primary registration for ART.

The 95 % confidence intervals (CI) are reported where relevant. The median CD4 count at the ART initiation is presented for the alive, dead and LFU patients separately and range is also reported. Log rank test was used to examine the test of significance for survival probability. Data from 82 to 41 facilities were available for analysis in APT and RAJ, respectively. Data were analysed using the statistical software STATA (version 13.1, StatCorp, USA).

Results

A total of 3340 adult patient records were extracted for analysis in APT state of which 3280 (98.2 %) records had information available on the current status of the patient at the time of data collection. Among these, 2130 (64.9 %) were alive and on ART, 437 (13.3 %) had died, 432 (13.2 %) were LFU, and 281 (8.6 %) were transferred out to another ART facility during the study period. In RAJ state, 3241 adult patient records were extracted for analysis of which 3198 (98.7 %) had information available on the current status of the patient at the time of data collection. Among these, 2554 (79.9 %) were alive and on ART, 393 (12.3 %) were dead, 115 (3.6 %) were LFU, and 136 (4.3 %) were transferred out to another ART facility.

The demographic and clinical characteristics of adult patients on ART are summarized in Table 1. The median age of patients on ART was 35 years in both states (Interquartile range, IQR 29–40 years). The median CD4 cell count at ART initiation was 172 cells/mm3 (IQR 104–236) in APT and 159 cells/mm3 (IQR 86–240) in RAJ. Significantly more patients had CD4 count of < =100 cells/mm3 at ART initiation in RAJ (29.4 %) than in APT (23.4 %; p < 0.001). The patients who were alive and on treatment showed an increasing trend in median CD4 cell counts at ART initiation over the years in both the states (Fig. 1). The overall baseline median CD4 cell count of deceased patients [126 cells/mm3 (IQR 66–194) in APT and 93 cells/mm3 (IQR 48–159) in RAJ) were comparatively lower than the patients who were alive and on treatment in both the states [184 cells/mm3 (IQR 115–245) in APT and 172 cells/mm3 (IQR 98–247) in RAJ].
Table 1

Demographic and clinical characteristics of patients on ART, and facility-related indicators in Andhra Pradesh and Telangana (2007-12) and in Rajasthan (2008-13)

 

Andhra Pradesh and Telangana (N = 3,340)a

Rajasthan (N = 3,241)b

Variables

Total (% of N)

Deceased (%)

Total (% of N)

Deceased (%)

Patient level

Year of ART initiationc

  2007-08

365 (10.9)

58 (15.9)

  

  2008-09

458 (13.7)

68 (14.9)

422 (13.0)

72 (17.1)

  2009-10

767 (23.0)

97 (12.7)

651 (20.1)

67 (10.3)

  2010-11

829 (24.8)

124 (15.0)

749 (23.1)

90 (12.0)

  2011-12

919 (27.5)

90 (9.8)

850 (26.2)

85 (10.0)

  2012-13

  

569 (17.6)

79 (13.9)

Sex of patient

  Male

1,724 (51.6)

273 (15.8)

1,860 (57.4)

285 (15.3)

  Female

1,561 (46.7)

159 (10.2)

1,360 (42.0)

108 (7.9)

Age of patients (years)

  16–29

857 (25.7)

98 (11.4)

720 (22.2)

66 (9.2)

  30–49

2,152 (64.4)

287 (13.3)

2,250 (69.4)

278 (12.4)

  = >50

329 (9.9)

52 (15.8)

271 (8.4)

49 (18.1)

CD4 count at ART initiation (cells/mm3)

  < =100

782 (23.4)

168 (21.5)

954 (29.4)

209 (21.9)

  101–250

1,870 (56.0)

226 (12.1)

1,562 (48.2)

150 (9.6)

  >250

659 (19.7)

41 (6.2)

696 (21.5)

31 (4.5)

Co-existing tuberculosis

  No

2,823 (84.5)

336 (11.9)

2,582 (79.7)

276 (10.7)

  Yes

515 (15.4)

101 (19.6)

627 (19.4)

117 (18.7)

Ever use of alcohol

  No

2,739 (82.0)

319 (11.7)

2,709 (83.6)

299 (11.0)

  Yes

599 (17.9)

118 (19.7)

519 (16.0)

94 (18.1)

Baseline ART regimend

  STV based regimen with/without EFV

1,377 (41.2)

215 (15.6)

832 (25.7)

146 (17.6)

  ZDV based regimen with/without EFV

1,542 (46.2)

166 (10.8)

2,131 (65.8)

205 (9.6)

Facility level variables

Cumulative ART patient loade

  Below or equal to state average

1,891 (56.6)

262 (13.9)

1,621 (50.0)

190 (11.7)

  Above state average

1,449 (43.4)

175 (12.1)

1,620 (50.0)

203 (12.5)

Ratio of cumulative ART patients to pre-ART patientsf

  Below or equal to state average

1,998 (59.8)

275 (13.8)

2,433 (75.1)

271 (11.1)

  Above state average

1,342 (40.2)

162 (12.1)

808 (24.9)

122 (15.1)

Percent of cumulative loss to follow-up patients g

  Category 1

1,070 (32.0)

123 (11.5)

1,352 (41.7)

174 (12.9)

  Category 2

1,090 (32.6)

148 (13.4)

1,375 (42.4)

150 (10.9)

  Category 3

1,180 (35.3)

166 (14.1)

514 (15.9)

69 (13.4)

aData missing for Andhra Pradesh and Telangana: year of ART initiation for 2; sex of patients for 55; age of patients for 2; CD4 count at ART initiation for 29; co-existing tuberculosis for 2; ever use of alcohol for 2; baseline ART regimen for 421

bData missing for Rajasthan: sex of patients for 21; CD4 count at ART initiation for 29; co-existing tuberculosis for 32; ever use of alcohol for 13; baseline ART regimen for 278

cFinancial year

dSTV is Stavudine, ZDV is Zidovudine, and EFV is Efavirenz

eAverage for Andhra Pradesh and Telangana is 4844 and 4307 for Rajasthan

fFor Andhra Pradesh and Telangana is 0.59 and 0.70 for Rajasthan

gThe categories for Andhra Pradesh and Telangana are <5.6 %, >5.6–8.4 % and >8.4 %; and <3.1 %, 3.1–6.5 % and >6.5 % for Rajasthan

Fig. 1

Yearly trends in baseline median CD4 cell counts for HIV patients on ART in Andhra Pradesh and Telangana (2007-12) and in Rajasthan (2008-13) based on current status of the patient

Survival probability

Among the 437 and 393 patients who had died in APT and RAJ, respectively, 188 (43 %) in APT and 191 (48.6 %) patients in RAJ had died within 6 months of starting ART. The unadjusted mortality rate among patients on ART in APT and RAJ was 6.83 and 7.18 per 100 patient-years at 60 months, respectively. The median survival time was 22 months in APT and 18 months in RAJ.

The estimated unadjusted survival probability on ART at 12 and 60 months was 91.2 % (95 % CI 90.1–92.1) and 76.3 % (95 % CI 73.0–79.2) in APT, respectively; and 90.6 % (95 % CI 89.4–91.6) and 78.3 % (95 % CI 74.4–81.7) in RAJ (Fig. 2). The probability of survival was higher among females than males in both states (log rank test, p < 0.001; Fig. 2), and was significantly lower for patients with CD4 count <101 cells/mm3 at ART initiation than those with CD4 count >250 cells/mm3 in both the states (log rank test, p < 0.001; Fig. 3). After adjusting for the assumed higher mortality among LFU, the adjusted survival probability on ART at 60 months was 70.6 % (95 % UI 67.0–73.8) in APT and 76.1 % (95 % UI 72.2–79.6) in RAJ.
Fig. 2

Kaplan-Meier unadjusted survival curve for HIV patients on ART for males and females in Andhra Pradesh and Telangana (2007-12) and Rajasthan (2008-13)

Fig. 3

Kaplan-Meier unadjusted survival curve for HIV infected patients on ART by CD4 count at ART initiation (cells/mm3) in Andhra Pradesh and Telangana (2007-12) and Rajasthan (2008-13)

Predictors of mortality

Table 2 shows the results with the Cox proportional hazard model for the predictors of mortality among HIV patients on ART. The findings at the patient level for both the states were similar. Patients with CD4 count <101 cells/mm3 at ART initiation had a higher hazard for mortality than patients with CD4 count >250 cells/mm3 (HR 3.36, 95 % CI 2.29–4.95 in APT and HR 3.71, 95 % CI 2.47–5.58 in RAJ). Patients with history of alcohol consumption had significantly higher risk of dying than who never consumed alcohol in APT (HR 1.57, 95 % CI 1.22–2.02) and in RAJ (HR 1.42, 95 % CI 1.09–1.86). Males as compared with females, and patients with TB co-infection had a higher hazard for death. The patients on Zidovudine-based ART regimen had a lower hazard for mortality than those on the Stavudine-based ART regimen in both states.
Table 2

Determinants of mortality among HIV patients on ART using Cox proportional hazard model for Andhra Pradesh and Telangana (2007-12) and Rajasthan (2008-13). CI denotes confidence interval

 

Andhra Pradesh and Telanganaa

Rajasthanb

Variables

Hazard ratio (95 % CI)

Hazard ratio (95 % CI)

Patient level variables

Sex of patient

  Male

1.36 (1.06–1.73)

1.83 (1.41–2.38)

  Female

1.00

1.00

Age of patients (years)

  16–29

1.00

1.00

  30–49

1.00 (0.77–1.29)

1.00 (0.75–1.34)

  = >50

1.24 (0.85–1.79)

1.25 (0.84–1.88)

CD4 count at ART initiation (cells/mm3)

  < =100

3.36 (2.29–4.95)

3.71 (2.47–5.58)

  101–250

1.94 (1.33–2.82)

1.73 (1.15–2.62)

  >250

1.00

1.00

Co-existing tuberculosis

  No

1.00

1.00

  Yes

1.42 (1.11–1.81)

1.31 (1.04–1.67)

Ever use of alcohol

  No

1.00

1.00

  Yes

1.57 (1.22–2.02)

1.42 (1.09–1.86)

Baseline ART regimenc

  STV based regimen with/without EFV

1.00

1.00

  ZDV based regimen with/without EFV

0.67 (0.55–0.83)

0.62 (0.50–0.78)

Facility level variables

Cumulative ART patient loadd

  Below or equal to state average

1.00

1.00

  Above state average

0.74 (0.57–0.95)

1.37 (1.01–1.87)

Ratio of cumulative ART patients to pre-ART patientse

  Below or equal to state average

1.00

1.00

  Above state average

0.90 (0.71–1.15)

1.62 (1.14–2.29)

Percent of cumulative loss to follow-up patientsf

  Category 1

1.00

1.00

  Category 2

1.16 (0.87–1.54)

1.22 (0.94–1.58)

  Category 3

1.47 (1.06–2.05)

1.40 (1.00–1.95)

aData missing for Andhra Pradesh and Telangana: year of ART initiation for 2; sex of patients for 55; age of patients for 2; CD4 count at ART initiation for 29; co-existing tuberculosis for 2; ever use of alcohol for 2; baseline ART regimen for 421

bData missing for Rajasthan: sex of patients for 21; CD4 count at ART initiation for 29; co-existing tuberculosis for 32; ever use of alcohol for 13; baseline ART regimen for 278

cSTV is Stavudine, ZDV is Zidovudine, and EFV is Efavirenz

dAverage for Andhra Pradesh and Telangana is 4844 and 4307 for Rajasthan

eFor Andhra Pradesh and Telangana is 0.59 and 0.70 for Rajasthan

fThe categories for Andhra Pradesh and Telangana are <5.6 %, >5.6–8.4 % and >8.4 %; and <3.1 %, 3.1–6.5 % and >6.5 % for Rajasthan

At the facility level, facilities with a cumulative ART patient load above the average for the state facilities had lower mortality in APT (HR 0.74, 95 % CI 0.57–0.95) but had higher mortality in RAJ (HR 1.37, 95 % CI 1.01–1.87). The facilities in APT with proportion of LFU patients higher than the state average had significantly higher mortality (HR 1.47, 95 % CI 1.06–2.05); the trend in RAJ was similar but did not reach statistical significance. On the other hand, facilities in RAJ with higher ART to pre-ART patient ratio had a significantly higher hazard for mortality (HR 1.62, 95 % CI 1.14–2.29).

Discussion

As public sector facilities provide ART to most patients in India, this sample of over 6500 adult patients on ART in two major states is fairly representative of a high and a low HIV burden state in India. This analysis of data covering 5 years reveals that the overall survival probability of HIV patients on ART at 60 months was reasonable at 76–78 %, and that the survival rates were similar in the high- and low-HIV burden states, with the former having a longer standing public funded ART program in place.

The survival rates in our data at 60 months are similar to those reported previously from three centres in southern India [3, 10]. Consistent with the published literature, a significant proportion of deaths occurred within the first 6 months of ART initiation [35, 7, 11]. Poor survival of males on ART as compared with females in our population has been documented previously from India and elsewhere [3, 6, 1216]. Factors such as poor treatment seeking behaviour and non-adherence to treatment, and increased risk of LFU have been reported previously as possible reasons for higher mortality among males on ART [1720]. The median CD4 count at ART initiation was lower for males than females in both the states, and 58 % of LFU in APT and 65 % in RAJ were males in our study. This finding suggests that it would be useful for the HIV services to make males more aware of the benefits of timely initiation of ART for better survival outcome. Both a low CD4 count at ART initiation and co-existing TB have been previously reported to be associated with poorer survival outcomes among Indian patients [3, 4, 17, 2123]. The overall median CD4 count at ART initiation in this study had increased significantly over the 5 years in both APT (154 to 193) and RAJ (132 to 174). However, these data were not for those who had died. As a lower CD4 count is associated with delayed ART initiation and with higher attrition while on treatment, [17, 22] the program could focus more on ensuring adherence and follow-up of the patients with lower CD4 count to further improve the survival outcomes. With regard to TB, NACP-IV has clearly identified HIV-TB coordination including cross-referral, detection and treatment as one of the objectives in the revised strategy that aims to further the integration between HIV and TB services, [24] in particular to prevent LFU and early initiation of ART [2527].

Inclusion of data from a large number of facilities in this study allowed assessment of facility-level variables that influence survival on ART. These findings are relevant for program planning. The ART patient load was an important predictor of mortality in both states, albeit differently. In APT, facilities with a higher load had better survival outcomes possibly because of a longer established ART program that has likely acquired more experience leading to better outcomes. However, in RAJ, facilities with higher ART patient load had poorer survival outcome, as did facilities with a higher ratio of ART to pre-ART patients. This higher patient load in the less experienced ART program in RAJ may be resulting in difficulty in handling patients, which indicates the need for strengthening facilities in RAJ with high or increasing ART load through monitoring of their human resources, supplies and infrastructure. In addition, even though both states had more pre-ART than ART patients across the facilities, the average ART to pre-ART patient ratio was relatively higher in RAJ.

The reasonable survival outcomes in the two states, which were not significantly different from each other without and with adjusting for mortality in the LFU patients, are encouraging for the national HIV program. Over the study period, the LFU proportion remained fairly consistent in APT, and was similar to that reported previously [17, 22]. Factors associated with poor patient retention have been documented for APT, [17, 22] and more effective and robust tracking of LFU is needed to improve survival outcomes. The significantly lower proportion of LFU in RAJ was a likely a result of a recent exercise carried out by the State AIDS Control Society to trace LFUs in order to bring them back to the treatment cycle. It is possible that some LFU patients may have initiated ART at another facility. However, it is not possible to track mobility of individual patients between the ART facilities in the program yet. To address this challenge, NACO is considering use of SMART cards with biometric identification for each patient which could facilitate not only tracking of patients but also potentially improve adherence and access to treatment [28].

Our study limitations include missing data, non-usable information on treatment adherence in the white cards, and survival status of transferred out and LFU patients as these were not readily available in the patient records. Despite these limitations, these large sample data collected from routine patient records are generalizable as all ART centres in both states were included. Data utilised for this study were obtained from paper forms/registers used in routine service conditions by the providers in the facilities, and thus are reflective of the ground reality.

Conclusions

In conclusion, these data have highlighted the benefits of investment in ART in India which is associated with a reasonably good over survival rate at 5 years, and have identified important determinants of survival on ART at the facility-level in addition to patient-level factors that can inform improvement of the ART services in India. An important program-relevant message from these findings is that ART survival could potentially be improved further if facilities with higher load get specific attention in the initial phase in Indian states with a more recent ART program.

Abbreviations

AIDS: 

Acquired immunodeficiency syndrome

APT: 

Andhra Pradesh and Telangana

ART: 

Antiretroviral therapy

CI: 

Confidence interval

HIV: 

Human immunodeficiency virus

HR: 

Hazard ratio

LAC: 

Link ART centre

LFU: 

Lost to follow-up

NACP: 

National AIDS Control Programme

NACO: 

National AIDS Control Organisation

UI: 

Uncertainty interval

RAJ: 

Rajasthan

TB: 

Tuberculosis

Declarations

Acknowledgments

The authors would like to acknowledge all individuals who contributed to this study, including the State AIDS Control Societies and facility staff who gave their time for facilitating access to white cards and to complete survey components; and the field team members who conducted data collection.

Funding

Funding for this work was provided by the Bill & Melinda Gates Foundation.

Availabilty of data and material

Data are available with the corresponding author, and can be made available on request.

Authors’ contributions

RD, LD, BBR, GAK, ST and EG were responsible for the study design. SGPK and SPR were responsible for overseeing data collection. GAK and VVS were responsible for data management. RD, GAK, SGPK, VVS and ST were involved with data analysis. RD and GAK drafted the original manuscript. LD, BBR, HD and EG gave significant inputs for analysis and interpretation. All authors had full access to the data, and have read and approved the final manuscript.

Competing interest

BBR and ST are affiliated with the Department of AIDS Control, Ministry of Health and Family Welfare, Government of India that oversees the ART Programme in India. LD is on the Editorial Board for the journal BMC Medicine.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Ethics approval for this study was obtained from Ethics Committees of the Public Health Foundation of India, New Delhi and the University of Washington, Seattle, USA. The study was also approved by the Indian Council for Medical Research, Health Ministry Steering Committee, the Government of India and by the National AIDS Control Organization of India. As the data collection involved retrospective review of patient records with no identifiable information to be collected, the consent to participate from patients was exempted by the Ethics Committee as this research was designed to study benefit of a public service programme.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Public Health Foundation of India
(2)
Department of AIDS Control, Ministry of Health and Family Welfare, Government of India
(3)
World Health Organization Country Office for India
(4)
Institute for Health Metrics and Evaluation, University of Washington

References

  1. NACP-IV components. [http://www.naco.gov.in/nacp-iv-components]. Accessed 5 Oct 2016.
  2. NACP-IV Programme Priorities and Thrust Areas. [http://www.naco.gov.in/programme-priorities-and-thrust-areas-0]. Accessed 5 Oct 2016.
  3. Allam RR, Murhekar MV, Bhatnagar T, Uthappa CK, Chava N, Rewari BB, Venkatesh S, Mehendale S. Survival probability and predictors of mortality and retention in care among patients enrolled for first-line antiretroviral therapy, Andhra Pradesh, India, 2008-2011. Trans R Soc Trop Med Hyg. 2014;108(4):198–205.View ArticlePubMedGoogle Scholar
  4. Bachani D, Garg R, Rewari BB, Hegg L, Rajasekaran S, Deshpande A, Emmanuel KV, Chan P, Rao KS. Two-year treatment outcomes of patients enrolled in India’s national first-line antiretroviral therapy programme. Natl Med J India. 2010;23(1):7–12.PubMedGoogle Scholar
  5. Ghate M, Deshpande S, Tripathy S, Godbole S, Nene M, Thakar M, Risbud A, Bollinger R, Mehendale S. Mortality in HIV infected individuals in Pune, India. Indian J Med Res. 2011;133:414–20.PubMedPubMed CentralGoogle Scholar
  6. Rajeev A, Sharma A. Mortality and morbidity patterns among HIV patients with prognostic markers in a tertiary care hospital in southern India. Australa Med J. 2011;4(5):273–6.View ArticleGoogle Scholar
  7. Sharma SK, Dhooria S, Prasad KT, George N, Ranjan S, Gupta D, Sreenivas V, Kadhiravan T, Miglani S, Sinha S, et al. Outcomes of antiretroviral therapy in a northern Indian urban clinic. Bull World Health Organ. 2010;88(3):222–6.View ArticlePubMedPubMed CentralGoogle Scholar
  8. NACO Annual Report 2014-15. [http://www.naco.gov.in/sites/default/files/annual_report%20_NACO_2014-15_0.pdf]. Accessed 5 Oct 2016.
  9. Egger M, Spycher BD, Sidle J, Weigel R, Geng EH, Fox MP, MacPhail P, van Cutsem G, Messou E, Wood R, et al. Correcting mortality for loss to follow-up: a nomogram applied to antiretroviral treatment programmes in sub-Saharan Africa. PLoS Med. 2011;8(1):e1000390.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Ghate M, Tripathy S, Gangakhedkar R, Thakar M, Bhattacharya J, Choudhury I, Risbud A, Bembalkar S, Kadam D, Rewari BB, et al. Use of first line antiretroviral therapy from a free ART programme clinic in Pune, India - A preliminary report. Indian J Med Res. 2013;137(5):942–9.PubMedPubMed CentralGoogle Scholar
  11. Rajasekaran S, Jeyaseelan L, Raja K, Vijila S, Krithigaipriya KA, Kuralmozhi R. Increase in CD4 cell counts between 2 and 3.5 years after initiation of antiretroviral therapy and determinants of CD4 progression in India. J Postgrad Med. 2009;55(4):261–6.View ArticlePubMedGoogle Scholar
  12. Druyts E, Dybul M, Kanters S, Nachega J, Birungi J, Ford N, Thorlund K, Negin J, Lester R, Yaya S, et al. Male sex and the risk of mortality among individuals enrolled in antiretroviral therapy programs in Africa: a systematic review and meta-analysis. AIDS. 2013;27(3):417–25.View ArticlePubMedGoogle Scholar
  13. Rai S, Mahapatra B, Sircar S, Raj PY, Venkatesh S, Shaukat M, Rewari BB. Adherence to Antiretroviral Therapy and Its Effect on Survival of HIV-Infected Individuals in Jharkhand, India. PLoS One. 2013;8(6):e66860.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Sieleunou I, Souleymanou M, Schönenberger AM, Menten J, Boelaert M. Determinants of survival in AIDS patients on antiretroviral therapy in a rural centre in the Far-North Province, Cameroon. Trop Med Int Health. 2009;14(1):36–43.View ArticlePubMedGoogle Scholar
  15. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, Mtonga V, Reid S, Cantrell RA, Bulterys M, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA. 2006;296(7):782–93.View ArticlePubMedGoogle Scholar
  16. Mills EJ, Bakanda C, Birungi J, Chan K, Hogg RS, Ford N, Nachega JB, Cooper CL. Male gender predicts mortality in a large cohort of patients receiving antiretroviral therapy in Uganda. J Int AIDS Soc. 2011;14:52.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Alvarez-Uria G, Naik PK, Pakam R, Midde M. Factors associated with attrition, mortality, and loss to follow up after antiretroviral therapy initiation: data from an HIV cohort study in India. Glob Health Action. 2013;6:21682.View ArticleGoogle Scholar
  18. Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, Regensberg L, Chaisson RE, Maartens G. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr. 2006;43(1):78–84.View ArticlePubMedGoogle Scholar
  19. Ochieng-Ooko V, Ochieng D, Sidle JE, Holdsworth M, Wools-Kaloustian K, Siika AM, Yiannoutsos CT, Owiti M, Kimaiyo S, Braitstein P. Influence of gender on loss to follow-up in a large HIV treatment programme in western Kenya. Bull World Health Organ. 2010;88(9):681–8.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Cornell M, Schomaker M, Garone DB, Giddy J, Hoffmann CJ, Lessells R, Maskew M, Prozesky H, Wood R, Johnson LF, et al. Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study. PLoS Med. 2012;9(9):e1001304.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Bhowmik A, Bhandari S, De R, Guha SK. Predictors of mortality among HIV-infected patients initiating anti retroviral therapy at a tertiary care hospital in eastern India. Asian Pac J Trop Med. 2012;5(12):986–90.View ArticlePubMedGoogle Scholar
  22. Alvarez-Uria G, Pakam R, Midde M, Naik PK. Predictors of delayed antiretroviral therapy initiation, mortality, and loss to followup in HIV infected patients eligible for HIV treatment: data from an HIV cohort study in India. Biomed Res Int. 2013;2013:849042.PubMedPubMed CentralGoogle Scholar
  23. Rupali P, Mannam S, Bella A, John L, Rajkumar S, Clarence P, Pulimood SA, Samuel P, Karthik R, Abraham OC, et al. Risk factors for mortality in a south Indian population on generic antiretroviral therapy. J Assoc Physicians India. 2012;60:11–4.PubMedGoogle Scholar
  24. NACP IV Strategy document. [http://www.naco.gov.in/sites/default/files/Strategy_Document_NACP%20IV.pdf]. Accessed 5 Oct 2016.
  25. Gupta AK, Singh GP, Goel S, Kaushik PB, Joshi BC, Chakraborty S. Efficacy of a new model for delivering integrated TB and HIV services for people living with HIV/AIDS in Delhi -- case for a paradigm shift in national HIV/TB cross-referral strategy. AIDS Care. 2014;26(2):137–41.View ArticlePubMedGoogle Scholar
  26. Vijay S, Kumar P, Chauhan LS, Rao SV, Vaidyanathan P. Treatment outcome and mortality at one and half year follow-up of HIV infected TB patients under TB control programme in a district of South India. PLoS One. 2011;6(7):e21008.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Vijay S, Swaminathan S, Vaidyanathan P, Thomas A, Chauhan LS, Kumar P, Chiddarwar S, Thomas B, Dewan PK. Feasibility of provider-initiated HIV testing and counselling of tuberculosis patients under the TB control programme in two districts of South India. PLoS One. 2009;4(11):e7899.View ArticlePubMedPubMed CentralGoogle Scholar
  28. National AIDS Control Programme. Journey of ART programme in India: story of a decade. New Delhi:Ministry of Health and Family Welfare, Government of India; 2014.Google Scholar

Copyright

© The Author(s). 2016